Mammalian telomeres repress DNA-damage activation at natural chromosome ends by recruiting specific inhibitors of the DNAdamage machinery that form a protective complex termed shelterin. Within this complex, TRF2 (also known as TERF2) has a crucial role in end protection through the suppression of ATM activation and the formation of end-to-end chromosome fusions 1,2 .
Mammalian telomeres repress DNA-damage activation at natural chromosome ends by recruiting specific inhibitors of the DNAdamage machinery that form a protective complex termed shelterin. Within this complex, TRF2 (also known as TERF2) has a crucial role in end protection through the suppression of ATM activation and the formation of end-to-end chromosome fusions 1, 2 .
Here we address the molecular properties of TRF2 that are both necessary and sufficient to protect chromosome ends in mouse embryonic fibroblasts. Our data support a two-step mechanism for TRF2-mediated end protection. First, the dimerization domain of TRF2 is required to inhibit ATM activation, the key initial step involved in the activation of a DNA-damage response (DDR). Next, TRF2 independently suppresses the propagation of DNAdamage signalling downstream of ATM activation. This novel modulation of the DDR at telomeres occurs at the level of the E3 ubiquitin ligase RNF168 (ref. 3 ). Inhibition of RNF168 at telomeres involves the deubiquitinating enzyme BRCC3 and the ubiquitin ligase UBR5, and is sufficient to suppress chromosome end-to-end fusions. This two-step mechanism for TRF2-mediated end protection helps to explain the apparent paradox of frequent localization of DDR proteins at functional telomeres without concurrent induction of detrimental DNA-repair activities.
In mammalian cells, protection of chromosome ends requires TRF2 (ref. 4) . When telomeres become critically short, insufficient recruitment of TRF2 leads to telomere de-protection and initiation of a DDR at chromosome termini. Indeed, TRF2-depleted telomeres elicit the same response as critically short telomeres, such as the recruitment of DDR factors (for example, MDC1, RNF8 and 53BP1 (also known as TP53BP1)) 2, 5, 6 , activation of a cell cycle checkpoint and subsequent repair activities resulting in end-to-end chromosome fusions 1, 7 . Among the telomere-binding proteins, TRF2 is unique in its ability to suppress the ATM-dependent DDR pathway and the non-homologous endjoining pathway 2, 8 .
To define the unique molecular properties of TRF2 that are involved in end protection, we performed a domain-swapping approach between TRF2 and the structurally similar but functionally divergent telomere-binding protein TRF1 (ref. 9; also known as TERF1). TRF2 and TRF1 are both composed of four domains: a carboxy-terminal MYB domain required for binding to double-stranded telomeric DNA (TTAGGG), a flexible hinge domain involved in protein-protein interaction, a TRFH domain required for homodimerization 9 and a divergent amino-terminal domain (Fig. 1a ). The N-terminal domain of TRF2 is rich in basic residues (basic domain), whereas the TRF1 N-terminal domain is composed of acidic residues (acidic domain) ( Fig. 1a ). We generated a set of chimaeric telomere repeat factors (TRF c ) in which TRF2 domains were replaced by the analogous TRF1 domains. The resulting constructs were tested for their ability to complement for the loss of endogenous TRF2 using TRF2 conditional (Trf2 floxed/floxed ) mouse embryonic fibroblasts (MEFs) 1 . To ensure synchronous and complete TRF2 depletion we used Trf2 floxed/floxed cells carrying an inducible Cre recombinase (Rosa26-CreERT2) that can be activated by 4-hydroxytamoxifen ( Supplementary Fig. 1 ). All TRF c constructs analysed showed the expected telomere localization in the presence or absence of endogenous TRF2 ( Supplementary Fig. 2a-d ). Importantly, ectopic TRF1 expression cannot complement for the loss of TRF2, as frequent DNA-damage foci at telomeres-termed telomereinduced foci (TIF)-and chromosome end-to-end fusions still appear ( Fig. 1b-d ). Conversely, a TRF2 construct that lacks the N-terminal basic domain (TRF2 DB ) is able to suppress TIF formation and end-toend chromosome fusions ( Fig. 1b-d ). Similarly, a TRF2 construct in which the DNA-binding domain was replaced with the TRF1 MYB domain (TRF cM ) can complement for loss of TRF2 ( Fig. 1b-d ). These data show that, in vivo, the specific ability of TRF2 to protect chromosome ends cannot be explained by a specificity of its DNA-binding domain, or by its unique N-terminal basic domain. By contrast, both the TRFH domain and the hinge domain of TRF2 are required to prevent the initial steps in the DDR pathway, as assessed by cH2AX localization at telomeres in cells expressing a construct containing either the TRFH domain (TRF cT ) or the hinge domain (TRF cH ) of TRF1 ( Fig. 1b, c) . Interestingly, we found that localization of TRF cT at telomeres is sufficient to inhibit the recruitment of key mediators of the DDR pathway downstream of cH2AX, such as 53BP1 ( Fig. 1c and Supplementary Figs 3a-c and 8). In agreement with this observation, TRF cT can also prevent chromosome fusions ( Fig. 1d , Supplementary Fig. 7 ), a process that requires 53BP1 recruitment 10, 11 . We rejected the hypothesis that TRF cT has a dominant-negative effect because its expression in TRF2-proficient cells does not result in DNA-damage induction ( Supplementary Fig. 5 ). By contrast, in cells expressing TRF cH , both cH2AX and 53BP1 localize to telomeres (Fig. 1b, c and Supplementary Fig. 3a -c). Interestingly, despite levels of TIFs that are comparable to those observed in TRF2-deficient (Trf2 2/2 ) cells, telomeres are partially protected from chromosome fusions ( Fig. 1d , Supplementary Fig. 7 and Supplementary Table 1 ). In agreement with that observed in Trf2 2/2 cells 2 , we found that the DDR initiated at TRF cT -or TRF cH -bound telomeres is ATM dependent (Supplementary Fig. 6 ). Our finding suggests that the TRFH domain is required to prevent the initial step of the DDR response, but that other portions of TRF2 can independently suppress propagation of this signal to downstream effectors. Next, we addressed the question of which step in the DDR response is inhibited by TRF2 by testing the localization of MDC1, RNF8 and RNF168 DNA-damage factors that are downstream of cH2AX and upstream of 53BP1 (ref. 12) . Upon TRF2 depletion, cH2AX, MDC1 and RNF8 localize to telomeres in cells expressing TRF cT , confirming that the TRF2 TRFH domain is required to prevent the initial steps in the DDR pathway ( Fig. 2a, b, d) . Similarly, we did not detect defects in SUMO1 accumulation at telomeres (data not shown). By contrast, the ubiquitin ligase RNF168 does not localize to TRF cT -bound telomeres ( Fig. 2c, d) . We exclude the possibility that this is due to a general inhibition of RNF168 activity in these cells as they readily form RNF168 irradiation-induced foci ( Supplementary Fig. 9 ). Recruitment of RNF168 at sites of damage is required for efficient 53BP1 recruitment 3, 13 , which in turn promotes chromosome fusions 11 .
To identify the critical region of TRF2 involved in the suppression of RNF168 recruitment, we focused on the hinge domain, given the high frequency of 53BP1 TIFs observed in cells expressing TRF cH (Fig. 1d ). The main function attributed to this domain until now has been the interaction with RAP1 and TIN2 (also known as TERF2IP and TINF2, respectively), two members of the shelterin complex that have been implicated in end protection [14] [15] [16] . We excluded a role for RAP1 in inhibiting RNF168 recruitment as deletion of the RAP1-interaction motif (amino acids 286-299) 17 in the context of the TRF cT construct did not result in 53BP1 localization to telomeres (Fig. 3a, b and Supplementary Fig. 11b) . Similarly, deletion of the TIN2-interaction motif (amino acids 352-367) 18 resulted only in a minor induction of 53BP1 accumulation, thus excluding a critical role for this interaction in the suppression of RNF168 at telomeres ( Fig. 3 a, b and Supplementary Fig. 11b ). This implicated the C-terminal portion of the hinge domain (amino acids 407-431), a region that by sequence alignment shows a high degree of conservation between species (Supplementary Fig. 10 ). Deletion of this region-which we have termed the inhibitor of DDR (iDDR) region-in the context of the TRF cT construct resulted in levels of 53BP1 that are comparable to those observed in Trf2 2/2 cells (Fig. 3a, b and Supplementary Fig. 11 ). To further validate this finding and to test whether this region is also sufficient to prevent DDR activation, we expressed the iDDR region in the context of TRF1 (Fig. 3a) . Notably, the resulting TRF1 iDDR protein can complement the phenotypes associated with TRF2 loss, with significant inhibition of 53BP1 and RNF168 localization and chromosome fusions (Fig. 3b, c and Supplementary Figs 11b, f and 12 ). By contrast, expression of TRF1 iDDR could not fully complement loss of TRF2 with regards to cH2AX localization at telomeres ( Fig. 3b and Supplementary  Fig. 11c ), a result that is in agreement with our data indicating a critical role for the TRFH domain of TRF2 in suppressing the initial activation of the DDR.
We then addressed the mechanism for the iDDR-dependent inhibition of RNF168 recruitment to dysfunctional telomeres. RNF168 is a ubiquitin ligase that is recruited to damaged chromatin by ubiquitin chains generated by the RNF8-UBC13 (also known as UBE2N) complex 3, 13 . Ubiquitinated proteins can be detected at dysfunctional telomeres with an antibody raised against conjugated ubiquitin (FK2; Supplementary Fig. 13e ). By contrast, we did not detect conjugated ubiquitin at TRF cT -bound telomeres ( Supplementary Fig. 13e ), suggesting a defective ubiquitin-mediated signalling in this context. Two mechanisms can explain this phenotype: inhibition of RNF8 activity, or LETTER RESEARCH recruitment of deubiquitinating enzymes (DUBs). Because RNF8 is localized at telomeres in cells expressing TRF cT (Fig. 2b) , we focused on the two DUB enzymes that have been shown to counteract the action of RNF8-UBC13 at sites of DNA damage: OTUB1 and BRCC3 (refs 19, 20) . We reasoned that if either of these DUBs has a role in TRF2-mediated end protection, reducing their levels should result in 53BP1 recruitment to telomeres in cells expressing TRF cT . Efficient (.90%) short hairpin RNA (shRNA)-mediated depletion of Otub1 did not result in 53BP1 foci formation ( Supplementary  Fig. 13a, b) . By contrast, two independent shRNA constructs directed against Brcc3 (with knockdown efficiencies of 95% and 98%; Supplementary Fig. 13c, d) resulted in the accumulation of 53BP1 and ubiquitin chains at telomeres in cells expressing TRF cT (Fig. 4a and Supplementary Fig. 13e ). Moreover, BRCC3 depletion in these cells resulted in levels of end-to-end chromosome fusions that are comparable to that observed in Trf2 2/2 cells ( Supplementary Fig. 14) . This latter result further corroborates the previous observation suggesting a critical role for 53BP1 localization for efficient DNA-repair events.
To verify whether BRCC3-mediated suppression of the DDR is associated with the iDDR region of TRF2, we tested whether Trf2 2/2 cells expressing TRF1 iDDR require BRCC3 expression to ensure end protection. Indeed, shRNA-mediated downregulation of Brcc3 in these cells abolishes the protective role of TRF1 iDDR , resulting in levels of 53BP1 localization and chromosome fusions that are comparable to the ones observed in Trf2 2/2 cells (Fig. 4a-c) .
To identify proteins that can be recruited at telomeres by the iDDR region of TRF2, Flag-tagged TRF1 iDDR was immunopurified and analysed by mass spectrometry ( Supplementary Fig. 17 and Supplementary Table 3 ). As a negative control, we used Flag-TRF1. The members of the MRE11 complex (MRE11 (also known as MRE11A), NBS1 (also known as NBN) and RAD50) and the ubiquitin ligase UBR5 were identified in TRF1 iDDR immunoprecipitates but not in TRF1 immunoprecipitates in three independent experiments ( Supplementary  Fig. 17 ). We confirmed that the iDDR region of TRF2 is required and sufficient to interact with RAD50 ( Fig. 4g) . Interestingly, the MRE11 complex has been shown to interact directly with BRCA1 (refs 21, 22) . We therefore proposed that members of the MRE11 complex could recruit BRCC3. Indeed, we found that NBS1 interacts with BRCC3 in co-immunoprecipitation experiments and can thus provide a physical link between TRF2 and BRCC3 ( Supplementary  Fig. 17f ). On the basis of these data we propose a model in which TRF2, by its established interaction with the MRE11 complex 23 , is able to recruit the BRCC3 enzyme at telomeres, which in turn can suppress RNF168 recruitment. However, we cannot rule out that additional unknown mechanisms may be involved in BRCC3 recruitment to telomeres. In addition, we found that the ubiquitin ligase UBR5 is required to mediate the iDDR-mediated end protection observed in Trf2 2/2 cells expressing TRF1 iDDR (Fig. 4d, e and Supplementary  Fig. 18 ). Recent reports have shown that UBR5 targets RNF168 for degradation 24 . We therefore propose a model in which RNF168 recruitment at telomeres is opposed by the action of BRCC3 and UBR5 (Fig. 4f) .
In summary, we found that two distinct regions within TRF2 are required to prevent activation of the DDR pathway at chromosome ends (Fig. 4f ). Our data indicate that the TRFH domain of TRF2 can prevent activation of the ATM pathway independently from other regions of TRF2. Together with previous observations, this suggests that this region might be involved in t-loop formation, a structural conformation of chromosome ends that has been proposed to hide the ends of chromosomes from the DNA-damage machinery 25 . In addition, we have identified a new function for TRF2 downstream of ATM activation and dependent on a portion of the hinge domain, here termed iDDR. TRF2 can sever the DNA-damage signalling cascade at the level of RNF168, preventing 53BP1 localization and, consequently, chromosome fusions. This finding provides a model to explain the apparent paradox of frequent localization of DNA-damage proteins at functional telomeres 23, 26 . Interestingly, in Schizosaccharomyces pombe, inhibition of Crb2 (the orthologue of mammalian 53BP1) recruitment at telomeres involves modulation of the methylation status of histone H4 (ref. 27) . Our data indicate that, in mammalian cells, a similar effect is achieved by inhibiting ubiquitindependent signalling at chromosome ends. This new end-protection role for TRF2 is mediated by the BRCA1 complex through its associated DUB enzyme BRCC3 and by the ubiquitin ligase UBR5. In support of a critical role for the BRCA1 complex in chromosome end protection and in agreement with previous reports 28, 29 , we show that inhibition of BRCA1, RAP80 (also known as UIMC1) or BRCC3 results in partial loss of end protection ( Supplementary Fig. 16 ). The identification of BRCC3 as a critical factor involved in TRF2dependent telomere protection suggests that an important physiological function of the BRCA1 complex is to maintain genomic stability by aiding telomere-associated proteins in maintaining telomere integrity.
METHODS SUMMARY
MEFs. MEFs were generated as described 1 , immortalized with Simian virus 40 large T antigen and treated with 4-hydroxytamoxifen (0.6 mM) to induce Cremediated recombination. Constructs. TRF c constructs were generated by PCR amplification (primers used are listed in Supplementary Table 2 ). pLDT-GFP-RNF8, pLDT-GFP-RNF168 and GFP-MDC1 were a gift from M. D. Weitzman. pOZ-FH-BRCC3 was obtained Vector shBrcc3
Trf2 were infected with Brcc3 (shBrcc3) or control (ctrl) shRNA, treated with OHT and stained for 53BP1 and telomere DNA. b, Quantification of staining in a. c, Metaphases of TRF1 iDDR -expressing cells treated as described in a were stained for telomere DNA (green) and DAPI (red). Percentages of chromosome fusions are indicated. d, TRF1 iDDR -expressing MEFs infected with Ubr5 (shUbr5) shRNA or a control shRNA were treated as described in a. e, Quantification of cells with 53BP1 colocalizing with cH2AX (or telomere DNA (TTAGGG)). Data are normalized to the control samples. f, Schematic of the proposed model for TRF2-mediated chromosome-end protection. Dashed lines indicate that additional factors may be involved. NHEJ, non-homologous end joining. g, HEK293 cells were transfected with the indicated constructs. Cell extracts were immunoprecipitated (IP) with anti-Flag resin and immunoblotted as indicated. NT, not treated.
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from Addgene. pcDNA-MYC-MRE11 and pcDNA-MYC-NBS1 were a gift from X. Wu. Antibodies. The following antibodies were used: MYC (9B11, Cell Signaling), CHK2 (BD Biosciences), hRAD50 (Novus, NB100-154SS), hUBR5 (Santa Cruz, sc-9562), Flag (Sigma, F7425), HA (Covance, 16B12), cH2AX (Millipore, JBW301), 53BP1 (Novus, NB 100-304), GFP (Invitrogen, A6455), BRCA1 (a gift from X. Yu), RNF168 (a gift from D. Durocher) and FK2 (Millipore, 04-263).
Purification of protein interacting with the iDDR region. HEK293 cells transfected with Flag-tagged TRF1 or Flag-tagged TRF1 iDDR were lysed, immunopurified using Flag resin, and samples analysed by nanoflow liquid chromatography mass spectrometry.
